Protein Summary
DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK2 may modulate the cellular proliferation induced by IL-4, as well as IL-2 and IL-3. May be involved in modulating Bcr-Abl signaling. Attenuates EGF-stimulated MAP kinase activation (By similarity). The protein encoded by this gene is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210(bcr/abl), a chimeric protein whose presence is associated with CML. This encoded protein binds p120 (RasGAP) from CML cells. [provided by RefSeq, Jul 2008]
- ENST00000276420
- ENSP00000276420
- ENSG00000147443
- p56DOK
- p56dok-2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
tissue sample | 0.69 | ||
cell type or tissue | 0.62 | ||
transcription factor binding site profile | 0.62 | ||
biological term | 0.6 | ||
hub protein | 0.58 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 43.95 (req: < 5)
Gene RIFs: 26 (req: <= 3)
Antibodies: 626 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 43.95 (req: >= 5)
Gene RIFs: 26 (req: > 3)
Antibodies: 626 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0